AdvanTIG-202: tislelizumab +/- ociperlimab in recurrent/metastatic cervical cancer

Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical CancerПодробнее

Investigating Combinations in Recurrent or Metastatic Cervical CancerПодробнее

Dr. Tewari on Trial With Cemiplimab in Recurrent or Metastatic Cervical CancerПодробнее

Pembrolizumab With Chemotherapy as First Line for Metastatic Cervical CancerПодробнее

Immunothearpy combo treating advanced cervical cancer | OSUCCC – JamesПодробнее

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular car...Подробнее

Metastatic and Recurrent Cervical Cancer TreatmentПодробнее

AdvanTIG-202: tislelizumab ± ociperlimab in recurrent/metastatic cervical cancerПодробнее

Dr. Monk on Bevacizumab in Recurrent Cervical CancerПодробнее

Dr. Isaacs Discusses the Role of Neratinib in HER2+ Breast CancerПодробнее

Dr. Krishnansu Tewari on a Phase III Trial Exploring Bevacizumab in Recurrent Cervical CancerПодробнее

Dr. Tewari on the Next Steps for Bevacizumab in Recurrent Cervical CancerПодробнее

Immune checkpoint inhibitors for endometrial and cervical cancerПодробнее

Bevacizumab in Advanced Cervical CancerПодробнее

Immunotherapy for Recurrent HNSCCПодробнее

Dr. Michael Birrer on Immunotherapy Potential in Cervical CancerПодробнее

Findings for Cemiplimab in Advanced or Recurrent Cervical CancerПодробнее

Gynecologic Oncology at ESMO Congress 2021: Trial Study in Cervical CancerПодробнее

KEYNOTE-B84: pepinemab + pembrolizumab for metastatic/recurrent head & neck squamous cell carcinomaПодробнее